# GlaxoSmithKline: Phase 1 study closed enrollment, 46 enrolled (Pneumonia, Bacterial)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose |
| NCT ID | NCT07406334 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Pneumonia, Bacterial |
| Intervention types | biological, combination product |
| Target enrollment | 46 |
| Site countries | South Africa |
| Posted | 2026-02-12 |
| Planned start | 2026-05-15 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07406334). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.